IQVIA Holdings slipped about 0.8% in the first trading session after its Q3 2026 release, a muted move for a stock that has quietly added roughly 9.7% over the past three months. The reaction looks modest next to what the company just put on the tape. Revenue reached about US$4.4b for the quarter, and adjusted earnings per share landed well above the basic US$2.13 figure, as management leaned on the contract research engine and data assets that drive this healthcare services platform.
The real story sits beyond a single quarter of solid contract wins and headline beats. Trailing earnings per share of a little over US$8 across the past year and a P/E of 32.1x now meet a balance sheet with about US$13.8b of net debt and cash flows that need to keep pulling their weight. Short term traders are reacting to the print. Long term holders are weighing whether this combination of growth profile, valuation gap and leverage works for their investment approach.
Love IQVIA Holdings' earnings power but uneasy about that US$13.8b net debt load and valuation premium at 32.1x P/E? Screen for healthcare peers with sturdier balance sheets and strong cash generation using our list of solid balance sheet and fundamentals stocks (24 results) .
Q3 2026 Earnings Summary
-
Total Revenue (Q3 2026 vs Q3 2025):US$4,428m vs. US$4,100m (up about 8%)
-
Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025):US$350m vs. US$331m (up about 6%)
-
Basic EPS (Q3 2026 vs Q3 2025):US$2.13 vs. US$1.94 (up about 9%)
-
Adjusted EBITDA Margin (Q3 2026 vs Q3 2025):approximately 23.2% vs. approximately 23.0% (expanded about 0.2 percentage points)
Earnings only capture part of IQVIA Holdings' story, since net income and EPS can look healthy while free cash generation tells you how easily that performance can support debt, reinvestment and potential capital returns. For readers who anchor decisions on cash produced rather than accounting profit, IQVIA Holdings' recent cash flow profile feeds into a discounted cash flow view where the stock could be a solid 25% undervalued .
IQVIA's AI Story Meets Hard Booking Milestones
The bullish pitch around IQVIA Holdings hinges on AI tools turning into real commercial wins rather than just a good slide in a deck.
"Bullish analysts expect IQVIA Holdings to keep gaining from AI enabled real world data and clinical tools, with recent AI agent deployment and contract wins reinforcing that this engine is still early in its commercial impact."
Q3 results give that claim some footing. R&D Solutions booked US$3.2b of new work with a 1.2 book to bill and last 12 month bookings up 14%, while management tied several wins directly to AI enabled protocol and site modeling. Commercial Solutions also saw record pipelines and faster decisions, which supports the idea that these tools are influencing client spend rather than just generating interest.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for .
IQVIA Bear Case: Privacy, In House AI, And What Q3 Shows
Bears argue IQVIA Holdings is vulnerable if customers move data work internally and clamp down on sharing.
"Bearish analysts expect IQVIA Holdings to face ongoing pressure on its analytics and clinical research services if clients respond to tighter data privacy scrutiny and greater in house AI adoption by reducing external spend and data sharing."
Q3 numbers do not show that squeeze yet. R&D Solutions bookings of US$3.2b with a 1.2 book to bill and last 12 month bookings up 14% point to clients still awarding sizeable work. Commercial Solutions revenue grew, with record pipelines and faster decisions. The risk here is more about potential future inflection points rather than anything visible in this quarter.
Hunt Quiet Mispricings After Earnings
IQVIA Holdings just showed how a detailed quarter can still leave investors debating the longer term setup. The real opportunity could sit in stocks that look misaligned with their underlying businesses before the market closes the gap.
-
Company 1 - 42% below our estimate - targets the shift to larger digital displays as software, services and retooled factories push into new projects.
-
Company 2 - 26% below our estimate - sells weight loss and diabetes injections that recently turned two flagship treatments into a massive franchise.
-
Company 3 - 34% below our estimate - builds AI focused cloud infrastructure that now underpins huge superclusters for a leading generative model provider.
Three companies from the same screener. Open all 29 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IQV .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
